Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
18 "Hye Jin Yoo"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Articles
Thyroid
Big Data Articles (National Health Insurance Service Database)
Unveiling Risk Factors for Treatment Failure in Patients with Graves’ Disease: A Nationwide Cohort Study in Korea
Jung A Kim, Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Endocrinol Metab. 2025;40(1):125-134.   Published online January 13, 2025
DOI: https://doi.org/10.3803/EnM.2024.2093
  • 6,417 View
  • 164 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Antithyroid drug (ATD) treatment is the preferred initial treatment for Graves’ disease (GD) in South Korea, despite higher treatment failure rates than radioactive iodine (RAI) therapy or thyroidectomy. This study aimed to evaluate the incidence of treatment failure associated with the primary modalities for GD treatment in real-world practice.
Methods
We included 452,001 patients diagnosed with GD between 2004 and 2020 from the Korean National Health Insurance Service-National Health Information Database. Treatment failure was defined as switching from ATD, RAI, or thyroidectomy treatments, and for ATD specifically, inability to discontinue medication for over 2 years.
Results
Mean age was 46.2 years, with females constituting 70.8%. Initial treatments for GD included ATDs (98.0%), thyroidectomy (1.3%), and RAI (0.7%), with a noted increment in ATD application from 96.2% in 2004 to 98.8% in 2020. During a median follow- up of 8.5 years, the treatment failure rates were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Multivariate analysis indicated that the hazard ratio for treatment failure with ATD was 2.81 times higher than RAI. RAI treatments ≥10 mCi had 37% lower failure rates than doses <10 mCi.
Conclusion
ATDs are the most commonly used for GD in South Korea, followed by thyroidectomy and RAI. Although the risk of treatment failure for ATD is higher than that of RAI therapy, initial RAI treatment in South Korea is relatively limited compared to that in Western countries. Further studies are required to evaluate the cause of low initial RAI treatment rates in South Korea.

Citations

Citations to this article as recorded by  
  • Nationwide Big Data Studies of Endocrine Diseases Using the Korean National Health Information Database: Research Trends and Standardization of Operational Definitions
    Sun Wook Cho, Jung Hee Kim, Kyoung Jin Kim, Beom-Jun Kim, Mee Kyoung Kim, Eun Jung Rhee
    Endocrinology and Metabolism.2026; 41(1): 86.     CrossRef
  • Treatment of Graves’ Disease: Faster Remission or Longer but Safe, That Is the Question
    Chan-Hee Jung
    Endocrinology and Metabolism.2025; 40(1): 70.     CrossRef
  • Process to radioactive iodine treatment for Graves’ hyperthyroidism: condemned or absolved?
    Luigi Bartalena, Daniela Gallo, George J. Kahaly, Eliana Piantanida, Maria Laura Tanda
    Journal of Endocrinological Investigation.2025; 48(9): 1927.     CrossRef
Close layer
Diabetes, obesity and metabolism
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)
Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong Jin, Jae Hyuk Lee, Gwanpyo Koh, Sang-Yong Kim, Jaetaek Kim, Ju Hee Lee, Tae Nyun Kim, Hyun Jeong Jeon, Ji Hyun Lee, Jae-Han Jeon, Hye Jin Yoo, Hee Kyung Kim, Hyeong-Kyu Park, Il Seong Nam-Goong, Seongbin Hong, Chul Woo Ahn, Ji Hee Yu, Jong Heon Park, Keun-Gyu Park, Chan Ho Park, Kyong Hye Joung, Ohk-Hyun Ryu, Keun Yong Park, Eun-Gyoung Hong, Bong-Soo Cha, Kyu Chang Won, Yoon-Sok Chung, Sin Gon Kim
Endocrinol Metab. 2024;39(5):722-731.   Published online August 22, 2024
DOI: https://doi.org/10.3803/EnM.2024.1995
  • 14,288 View
  • 367 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined.
Methods
This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months.
Conclusion
This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.

Citations

Citations to this article as recorded by  
  • Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
    Mengying Liu, Seok Ting Lim, Weihua Song, Thomas M. Coffman, Xiaomeng Wang
    Trends in Pharmacological Sciences.2026; 47(3): 325.     CrossRef
  • Differential Pre‐ and Post‐Treatment Effects of Low‐Dose Antidyslipidemic Drugs on Gentamicin‐Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study
    Pitchai Balakumar, Sultan Alshahrani, Noohu Abdulla Khan, Rajavel Varatharajan, K. M. Sundram
    Journal of Applied Toxicology.2026; 46(6): 1879.     CrossRef
  • Ezetimibe attenuates diabetic retinopathy via NRF2-mediated suppression of inflammation and oxidative stress
    Lei Cheng, Shan Cheng, Ran Zhu, Guoxu Xu
    Journal of Diabetes and its Complications.2026; 40(2): 109250.     CrossRef
  • Development and Validation of Green UV Spectrophotometric Method Using Augmented Classical Least Squares for Simultaneous Quantification of Atorvastatin, Ezetimibe, and Fenofibrate in Pharmaceutical and Environmental Samples
    Ahmed M. Abdelzaher, Omkulthom Al kamaly, Anwar M. Alnakhli, Mona A. Abdel Rahman
    ChemistrySelect.2026;[Epub]     CrossRef
  • Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
    Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold
    Pharmaceuticals.2025; 18(2): 147.     CrossRef
  • Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study
    Ji Yoon Kim, Nam Hoon Kim, Jiyoon Lee, Dong-Hoon Kim, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2025; 11(7): 620.     CrossRef
Close layer
Miscellaneous
AM1638, a GPR40-Full Agonist, Inhibited Palmitate- Induced ROS Production and Endoplasmic Reticulum Stress, Enhancing HUVEC Viability in an NRF2-Dependent Manner
Hwan-Jin Hwang, Joo Won Kim, SukHwan Yun, Min Jeong Park, Eyun Song, Sooyeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Endocrinol Metab. 2023;38(6):760-769.   Published online November 2, 2023
DOI: https://doi.org/10.3803/EnM.2023.1774
  • 7,205 View
  • 137 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
G protein-coupled receptor 40 (GPR40) is a key molecule in diabetes and fatty liver, but its role in endothelial dysfunction remains unclear. Our objective in this study was to determine whether GPR40 agonists protect endothelial cells against palmitatemediated oxidative stress.
Methods
Human umbilical vein endothelial cells (HUVECs) were used to investigate effects of various GPR40 agonists on vascular endothelium.
Results
In HUVECs, AM1638, a GPR40-full agonist, enhanced nuclear factor erythroid 2–related factor 2 (NRF2) translocation to the nucleus and heme oxygenase-1 (HO-1) expression, which blocked palmitate-induced superoxide production. Those antioxidant effects were not detected after treatment with LY2922470 or TAK875, GPR40-partial agonists, suggesting that GPR40 regulates reactive oxygen species (ROS) removal in a ligand-dependent manner. We also found that palmitate-induced CCAAT/enhancer‐binding protein homologous protein expression; X-box binding protein-1 splicing, nuclear condensation, and fragmentation; and caspase-3 cleavage were all blocked in an NRF2-dependent manner after AM1638 treatment. Both LY2922470 and TAK875 also improved cell viability independent of the NRF2/ROS pathway by reducing palmitate-mediated endoplasmic reticulum stress and nuclear damage. GPR40 agonists thus have beneficial effects against palmitate in HUVECs. In particular, AM1638 reduced palmitate-induced superoxide production and cytotoxicity in an NRF2/HO-1 dependent manner.
Conclusion
GPR40 could be developed as a good therapeutic target to prevent or treat cardiovascular diseases such as atherosclerosis.

Citations

Citations to this article as recorded by  
  • From oxidative stress to metabolic dysfunction: The role of TRPM2
    Ying-Shuang Li, Hua-Cheng Ren, Hui Li, Man Xing, Jian-Hua Cao
    International Journal of Biological Macromolecules.2025; 284: 138081.     CrossRef
  • Discovery of potent free fatty acid receptor 1 full agonists with a novel scaffold bearing conjugated double bond linker
    Ziwei Yang, Jun Sun, Tifei Xu, Yu Wang, Jiahui Fang, Kai Wang, Shimeng Guo, Xin Xie, Jianhua Shen
    Bioorganic & Medicinal Chemistry.2025; 123: 118158.     CrossRef
  • GPR40-full agonist AM1638 alleviates palmitate-induced oxidative damage in H9c2 cells via an AMPK-dependent pathway
    SukHwan Yun, Joo Won Kim, Min Jeong Park, Eyun Song, Soo Yeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hwan-Jin Hwang, Hye Jin Yoo
    BMB Reports.2025; 58(3): 133.     CrossRef
  • HD6277 Suppresses Muscle Atrophy by Promoting Myogenic Factors and Inhibiting Proteolysis in Aged Mice
    Joo Won Kim, SukHwan Yun, Min Jeong Park, Eyun Song, Sooyeon Jang, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hwan‐Jin Hwang, Hye Jin Yoo
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Sarcopenic obesity: prospects of mitochondrial transplantation to combat metabolic deterioration in aging
    Md Ariful Islam, Wenyi Gu, Yijie Song, Yu Xu, Hongxi Xu
    Acta Materia Medica.2025;[Epub]     CrossRef
  • Molecular mechanisms of aberrant fatty acids metabolism in driving cardiovascular diseases: key regulatory targets and dietary interventions
    Rui Yang, Jiao Pang, Xue Zhong, Shuyang Pang, Xuefeng Hu, Chenfei Wei, Weiqi Yan, Xueting Chen, Rui Zhao, Baojun Xu, Zhipeng Cao
    Food & Function.2025; 16(15): 5961.     CrossRef
  • Hypoglycemic and Analgesic Effects of Benzyloxyphenylpropanoic Derivatives of Isobornylamine as FFAR‐1 Agonists
    Mariya A. Elkina, Mikhail V. Khvostov, Sergey O. Kuranov, Olga A. Luzina, Natalia A. Zhukova, Yulia V. Meshkova, Tatiana G. Tolstikova, Nariman F. Salakhutdinov
    Archiv der Pharmazie.2025;[Epub]     CrossRef
  • Free Fatty Acids and Free Fatty Acid Receptors: Role in Regulating Arterial Function
    Fengzhi Yu, Boyi Zong, Lili Ji, Peng Sun, Dandan Jia, Ru Wang
    International Journal of Molecular Sciences.2024; 25(14): 7853.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Sleep Duration and the Risk of Type 2 Diabetes: A Community-Based Cohort Study with a 16-Year Follow-up
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Seung Ku Lee, Chol Shin, Nan Hee Kim
Endocrinol Metab. 2023;38(1):146-155.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1582
  • 14,820 View
  • 364 Download
  • 18 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
We aimed to investigate the moderating effects of obesity, age, and sex on the association between sleep duration and the development of diabetes in Asians.
Methods
We analyzed data from a cohort of the Korean Genome and Epidemiology Study conducted from 2001 to 2020. After excluding shift workers and those with diabetes at baseline, 7,407 participants were stratified into three groups according to sleep duration: ≤5 hours/night, >5 to 7 hours/night (reference), and >7 hours/night. The Cox proportional hazards analyses were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes mellitus (T2DM). Subgroup analyses were performed according to obesity, age, and sex.
Results
During 16 years of follow-up, 2,024 cases of T2DM were identified. Individuals who slept ≤5 h/night had a higher risk of incident diabetes than the reference group (HR, 1.17; 95% CI, 1.02 to 1.33). The subgroup analysis observed a valid interaction with sleep duration only for obesity. A higher risk of T2DM was observed in the ≤5 hours/night group in non-obese individuals, men, and those aged <60 years, and in the >7 hours/night group in obese individuals (HRs were 1.34 [95% CI, 1.11 to 1.61], 1.22 [95% CI, 1 to 1.49], and 1.18 [95% CI, 1.01 to 1.39], respectively).
Conclusion
This study confirmed the effect of sleep deprivation on the risk of T2DM throughout the 16-year follow-up period. This impact was confined to non-obese or young individuals and men. We observed a significant interaction between sleep duration and obesity.

Citations

Citations to this article as recorded by  
  • Glucose homeostasis during recurrent periods of sleep restriction and recovery in healthy young adults
    Yuki Y Y Cheung, Torance Y L Tan, Tiffany B Koa, Chin Meng Khoo, June C Lo
    SLEEPJ.2026;[Epub]     CrossRef
  • Mobile Phone Addiction and Sleep Quality Among Children and Adolescents: Unraveling the Health Consequences
    Ghizal Fatima, Vani Shukla, Aminat Magomedova, Rasul Magomedov
    Cureus.2026;[Epub]     CrossRef
  • Association of daytime circadian-aligned activity with glycemic control in type 2 diabetes: Insights from continuous glucose monitoring and wearable data
    Da Young Lee, Jung-Been Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Heon-Jeong Lee, Nan Hee Kim
    Metabolism.2026; 179: 156570.     CrossRef
  • The Role of Circadian Rhythm Dysregulation, Abnormal Sleep Patterns, and Sleep Disorders on the Development of Diabetes
    Hulya Merie, Bashair M. Mussa, Salah Abusnana
    Clocks & Sleep.2026; 8(2): 22.     CrossRef
  • Body-weight-specific and shared metabolomic responses to acute sleep loss in young adults
    Linnéa Good, Luiz Eduardo Mateus Brandão, Lieve Thecla van Egmond, Payam Emami Khoonsari, Ida Erngren, Henrik Carlsson, Robert Fredriksson, Kim Kultima, Christian Benedict, Jonathan Cedernaes
    Journal of Translational Medicine.2026;[Epub]     CrossRef
  • Association Between Sleep Duration and Glycemic Levels in Adults With Prediabetes: A Population-based Study
    Zhongqing Mou, Yan Zhou, Zaiquan Dong
    Canadian Journal of Diabetes.2026;[Epub]     CrossRef
  • Sleep features and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis
    Hongyi Liu, Hui Zhu, Qinkang Lu, Wen Ye, Tao Huang, Yuqiong Li, Bingqi Li, Yingxin Wu, Penghao Wang, Tao Chen, Jin Xu, Lindan Ji
    Annals of Medicine.2025;[Epub]     CrossRef
  • The potential impact of habitual sleep quality on glycaemic control and inflammation: A study on geriatric patients recently diagnosed with type 2 diabetes mellitus (T2DM)
    Nadia Hussain, Amal Hussain Ibrahim Al Haddad, Saima Abbass, Zina Alfahl
    Sleep Medicine: X.2025; 9: 100139.     CrossRef
  • The link between sleep duration and stroke risk
    Yu Cheng, Yuchuan Ding, Ahmed Elmadhoun, Xunming Ji, Xiaokun Geng
    Brain Circulation.2025; 11(1): 1.     CrossRef
  • Association between obstructive sleep apnea risk and atherosclerosis: A nationwide cross-sectional study in the Korean population
    Il Rae Park, Yong Geun Chung, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Qian Wu
    PLOS One.2025; 20(5): e0322897.     CrossRef
  • Case Report on the Improvement of Uncontrolled Blood Glucose with Shihogayonggolmoryo-tang, Yeonggyechulgam-tang, and Korean Medicine Complex Therapy
    Nahyun Cho, Chul-woo Ahn, Hyungsun Jun, Hyun-jong Jung, Dasol Park, Jungtae Leem
    The Journal of Internal Korean Medicine.2025; 46(3): 511.     CrossRef
  • The relationship between sleep patterns and the risk of edentulism: evidence from the CHARLS
    Hong-Yu Zhao, Peng-Lu Jia, Ping Ma, Wu-Long Jin, Hua-Jiao Yu
    Postgraduate Medical Journal.2025; 102(1203): 48.     CrossRef
  • Impact of Technological Advances on Type 2 Diabetes and Its Effect on Mental Health: A Perspective
    Varun Damle, Ankit Halder, Tanvi Damle
    Annals of Indian Psychiatry.2025;[Epub]     CrossRef
  • Reinterpreting Yangsaeng in Physiology on Korean Medicine for Geriatric Care: A Personalized Self-Care Model for Future Medicine
    Su Jin Lee, Young-Kyu Kwon
    Journal of Physiology & Pathology in Korean Medicine.2025; 39(6): 271.     CrossRef
  • Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
    Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(1): 37.     CrossRef
  • Role of Sleep and Sleep Disorders in Cardiometabolic Risk: a Review and Update
    Shaden O. Qasrawi, Ahmed S. BaHammam
    Current Sleep Medicine Reports.2024; 10(1): 34.     CrossRef
  • Evaluating reliability in wearable devices for sleep staging
    Vera Birrer, Mohamed Elgendi, Olivier Lambercy, Carlo Menon
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Replication Study of Genome Wide Association Study of Sleep Duration in Korean Association Resources Cohort
    Seok-Ho Cho, Seon-Ah Kim, Hyun-Seok Jin, Hong Sung Kim
    Biomedical Science Letters.2024; 30(2): 86.     CrossRef
  • Insights into optimal BMI from the GlasVEGAS study
    Chun-Kwan O, Juliana C. N. Chan
    Nature Metabolism.2024; 6(8): 1435.     CrossRef
  • Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer’s disease in elderly
    Upasana Mukherjee, Ujala Sehar, Malcolm Brownell, P. Hemachandra Reddy
    Ageing Research Reviews.2024; 100: 102457.     CrossRef
  • The Relationship Between the Risk of Type 2 Diabetes and Insomnia Severity and Sleep Duration in Academicians
    Tuğba Bilgehan, Esra Çalık Var
    Sağlık Bilimleri Üniversitesi Hemşirelik Dergisi.2024; 6(3): 203.     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The Link Between Sleeping and Type 2 Diabetes: A Systematic Review
    Ali Darraj
    Cureus.2023;[Epub]     CrossRef
Close layer
Brief Report
Diabetes, Obesity and Metabolism
Sestrin2 Regulates Beneficial β3-Adrenergic Receptor-Mediated Effects Observed in Inguinal White Adipose Tissue and Soleus Muscle
Min Jeong Park, Joo Won Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Hwan-Jin Hwang, Hye Jin Yoo
Endocrinol Metab. 2022;37(3):552-557.   Published online June 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.1421
  • 6,231 View
  • 139 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Sestrin2, a well-known adenosine monophosphate-activated protein kinase (AMPK) regulator, plays a protective role against metabolic stress. The β3-adrenergic receptor (β3AR) induces fat browning and inhibits muscle atrophy in an AMPK-dependent manner. However, no prior research has examined the relationship of sestrin2 with β3AR in body composition changes. In this study, CL 316,243 (CL), a β3AR agonist, was administered to wild-type and sestrin2-knockout (KO) mice for 2 weeks, and fat and muscle tissues were harvested. CL induced AMPK phosphorylation, expression of brown-fat markers, and mitochondrial biogenesis, which resulted in the reduction of lipid droplet size in inguinal white adipose tissue (iWAT). These effects were not observed in sestrin2-KO mice. In CL-treated soleus muscle, sestrin2-KO was related to decreased myogenic gene expression and increased levels of muscle atrophy-related molecules. Our results suggest that sestrin2 is associated with beneficial β3AR-mediated changes in body composition, especially in iWAT and in the soleus.

Citations

Citations to this article as recorded by  
  • The role of sestrin2 in skeletal muscle regeneration after injury
    Chae Young Hwang, Sang-Min Park, Hoyeon Lee, Seung-Min Lee, Jeong Yi Choi, Su-Jin Baek, Taeyoung Kim, Yong Ryoul Yang, Ki-Sun Kwon
    The Korean Journal of Physiology & Pharmacology.2026; 30(1): 19.     CrossRef
  • Sesn2 is Associated with Attenuated Muscle Atrophy and Altered Expression of Key Myogenic and Autophagy Markers in Mdx Mice
    Zubiao Song, Qing Lin, Jiahui Liang, Juanjuan He, Weixi Zhang
    Journal of Molecular Neuroscience.2026;[Epub]     CrossRef
  • Age-related changes in adrenergic regulation of contractility and redox status of glycolytic and oxidative skeletal muscles
    Julia G. Odnoshivkina, Guzel V. Sibgatullina, Svetlana A. Dmitrieva, Anastasia A. Ponomareva, Venera F. Khuzakhmetova, Ellya A. Bukharaeva, Alexey M. Petrov
    GeroScience.2025; 48(4): 5957.     CrossRef
  • Sestrin2 levels in patients with anxiety and depression myocardial infarction was up-regulated and suppressed inflammation and ferroptosis by LKB1-mediated AMPK activation
    Yufeng Qian, Lian Chen, Beibei Gao, Xianhua Ye
    Clinical and Experimental Hypertension.2023;[Epub]     CrossRef
  • Sestrin2 in diabetes and diabetic complications
    Xiaodan Zhang, Zirui Luo, Jiahong Li, Yaxuan Lin, Yu Li, Wangen Li
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
Close layer
Original Articles
Thyroid
Big Data Articles (National Health Insurance Service Database)
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study
Eyun Song, Min Ji Koo, Eunjin Noh, Soon Young Hwang, Min Jeong Park, Jung A Kim, Eun Roh, Kyung Mook Choi, Sei Hyun Baik, Geum Joon Cho, Hye Jin Yoo
Endocrinol Metab. 2021;36(6):1277-1286.   Published online December 16, 2021
DOI: https://doi.org/10.3803/EnM.2021.1251
  • 14,175 View
  • 227 Download
  • 15 Web of Science
  • 16 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains uncertain, with few longitudinal studies.
Methods
The risk of diabetes in patients with Graves’ disease treated with antithyroid drugs (ATDs) for longer than the conventional duration (≥2 years) was compared with that in age-and sex-matched controls. The risk was further compared according to subsequent treatment modalities after a 24-month course of ATD: continuation of ATD (ATD group) vs. radioactive iodine ablation (RIA) group.
Results
A total of 4,593 patients were included. Diabetes was diagnosed in 751 (16.3%) patients over a follow-up of 7.3 years. The hazard ratio (HR) for diabetes, after adjusting for various known risk factors, was 1.18 (95% confidence interval [CI], 1.10 to 1.28) in patients with hyperthyroidism. Among the treatment modality groups, the RIA group (n=102) had a higher risk of diabetes than the ATD group (n=4,491) with HR of 1.56 (95% CI, 1.01 to 2.42). Further, the risk of diabetes increased with an increase in the ATD treatment duration (P for trend=0.019).
Conclusion
The risk of diabetes was significantly higher in patients with long-standing Graves’ disease than in the general population, especially in patients who underwent RIA and prolonged ATD treatment. Special attention to hyperglycemia during follow-up along with effective control of hyperthyroidism may be necessary to reduce the risk of diabetes in these patients.

Citations

Citations to this article as recorded by  
  • Graves’ disease: review of disease characteristics, burden, and treatments
    Lesley-Ann Miller-Wilson, Erin Mandal, Kylle M. Tollefsen, Sarah Ronnebaum, Sofie Norregaard, Julie Chen
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Graves’ Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study
    Yoon Young Cho, Bongseong Kim, Sang-Man Jin, Chan-Hee Jung, Ji Oh Mok, Sun Wook Kim, Jae Hoon Chung, Kyung-Do Han, Tae Hyuk Kim
    Thyroid®.2025; 35(1): 60.     CrossRef
  • Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism
    Luigi Barrea, Massimiliano Caprio, Sebastio Perrini, Elisabetta Camajani, Andrea Crafa, Elena Gangitano, Stefania Gorini, Laura Sciacca, Ludovica Verde, Manuela Albertelli, Diego Ferone, Francesco Giorgino, Annamaria Colao, Gianluca Aimaretti, Giovanna Mu
    Journal of Endocrinological Investigation.2025; 48(8): 1739.     CrossRef
  • The Effect of Metformin on Prolactin Concentration in Women with Hyperprolactinemia and Subclinical Hyperthyroidism
    Robert Krysiak, Karolina Kowalcze, Bogusław Okopień
    Neuroendocrinology.2025; 115(6-7): 553.     CrossRef
  • Increased risk of multisystem comorbidities and disease trajectories following hyperthyroidism: evidence from the 0.5 million UK Biobank population
    Qiuyuan Chen, Doudou Chen, Xinpan Wang, Yunhao Zheng, Longyao Zhang, Zaiming Li, Xiaoyu Wu, Qin Chen, Ruyang Zhang, Feng Chen, Tao Yang, Xuqin Zheng, Yongyue Wei
    Endocrine Connections.2025;[Epub]     CrossRef
  • Safety of non-standard regimen of systemic steroid therapy in patients with Graves’ orbitopathy: a single-centre experience
    Nadia Sawicka-Gutaj, Dawid Gruszczyński, Natalia Zawalna, Kacper Nijakowski, Agnieszka Skiba, Mateusz Pochylski, Jerzy Sowiński, Marek Ruchała
    Pharmacological Reports.2024; 76(1): 185.     CrossRef
  • Increased risk of diabetes mellitus and hyperlipidemia in patients with differentiated thyroid cancer
    Hwa Young Ahn, Jooyoung Lee, Jinmo Kang, Eun Kyung Lee
    European Journal of Endocrinology.2024; 190(3): 248.     CrossRef
  • Evaluation of the Dysregulation of Cholesterol and Glucose Levels in Graves' Disease Using Clinical Data Analysis
    Zainab Razaq Kareem, Fatin Fadhel Al-Kazazz, Ahmed Mahdi Rheima, Ameer Radhi Sultan
    Reports of Biochemistry and Molecular Biology.2024; 13(2): 159.     CrossRef
  • Prevalencia de diabetes en personas con disfunción tiroidea
    Juan J. Díez, Pedro Iglesias
    Medicina Clínica.2023; 160(8): 333.     CrossRef
  • Control of Thyroid Dysfunction in Spanish Population Registered in the Primary Care Clinical Database: An Analysis of the Proportion of Patients with Thyrotropin Values Outside the Reference Range
    Juan J. Díez, Pedro Iglesias
    Hormone and Metabolic Research.2023; 55(03): 184.     CrossRef
  • Prevalence of thyroid dysfunction and its relationship to income level and employment status: a nationwide population-based study in Spain
    Juan J. Díez, Pedro Iglesias
    Hormones.2023; 22(2): 243.     CrossRef
  • Prevalence of diabetes in people with thyroid dysfunction
    Juan J. Díez, Pedro Iglesias
    Medicina Clínica (English Edition).2023; 160(8): 333.     CrossRef
  • Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities
    Mihaela Simona Popoviciu, Lorena Paduraru, Raluca Marinela Nutas, Alexandra Maria Ujoc, Galal Yahya, Kamel Metwally, Simona Cavalu
    International Journal of Molecular Sciences.2023; 24(16): 12676.     CrossRef
  • Thyroid Eye Disease and Its Association With Diabetes Mellitus: A Major Review
    Roshmi Gupta, Pramila Kalra, Lakshmi B. Ramamurthy, Suryasnata Rath
    Ophthalmic Plastic & Reconstructive Surgery.2023; 39(6S): S51.     CrossRef
  • Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves’ Disease
    Ho Yeop Lee, Byeong Chang Sim, Ha Thi Nga, Ji Sun Moon, Jingwen Tian, Nguyen Thi Linh, Sang Hyeon Ju, Dong Wook Choi, Daiki Setoyama, Hyon-Seung Yi
    Endocrinology and Metabolism.2022; 37(6): 891.     CrossRef
  • Diabetes and Hyperthyroidism: Is There a Causal Link?
    Sang Yong Kim
    Endocrinology and Metabolism.2021; 36(6): 1175.     CrossRef
Close layer
Clinical Study
Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults
Eyun Song, Min Ji Jeon, Hye Jin Yoo, Sung Jin Bae, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Hong-Kyu Kim, Won Gu Kim
Endocrinol Metab. 2021;36(2):365-373.   Published online April 7, 2021
DOI: https://doi.org/10.3803/EnM.2020.939
  • 11,883 View
  • 178 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Serum calcitonin measurement contains various clinical and methodological aspects. Its reference level is wide and unclear despite sensitive calcitonin kits are available. This study aimed to identify the specific reference range in the healthy Korean adults.
Methods
Subjects were ≥20 years with available calcitonin (measured by a two-site immunoradiometric assay) data by a routine health checkup. Three groups were defined as all eligible subjects (group 1, n=10,566); subjects without self or family history of thyroid disease (group 2, n=5,152); and subjects without chronic kidney disease, autoimmune thyroid disease, medication of proton pump inhibitor/H2 blocker/steroid, or other malignancies (group 3, n=4,638).
Results
This study included 6,341 male and 4,225 female subjects. Males had higher mean calcitonin than females (2.3 pg/mL vs. 1.9 pg/mL, P<0.001) in group 1. This gender difference remained similar in groups 2 and 3. Calcitonin according to age or body mass index was not significant in both genders. Higher calcitonin in smoking than nonsmoking men was observed but not in women. Sixty-nine subjects had calcitonin higher than the upper reference limit (10 pg/mL) and 64 of them had factors associated with hypercalcitoninemia besides medullary thyroid cancer. Our study suggests the reference intervals for men who were non, ex-, current smokers, and women (irrespective of smoking status) as <5.7, <7.1, <7.9, and <3.6 pg/mL, respectively.
Conclusion
Specific calcitonin reference range should be provided considering for sex and smoking status. Taking account for several factors known to induce hypercalcitoninemia can help interpret the gray zone of moderately elevated calcitonin.

Citations

Citations to this article as recorded by  
  • The Pitfalls of Calcitonin as a Tumor Marker: Real-Life Data of Patients with Elevated Basal Calcitonin Levels but Without Evidence of Medullary Thyroid Carcinoma
    Ann-Kathrin Lederer, Constantin-Leonard Jacob Kessler, Nabila Bouzakri, Oana Lozan, Florian Wild, Katharina Theresa Rauschkolb-Olk, Heidi Rossmann, Hauke Lang, Thomas J. Musholt
    Journal of Clinical Medicine.2026; 15(7): 2500.     CrossRef
  • Laboratory diagnostics and follow-up of medullary thyroid cancer
    Luca Giovanella, Federica D’Aurizio, Petra Petranović Ovčariček, Jacquelien J Hillebrand
    Journal of Molecular Endocrinology.2026;[Epub]     CrossRef
  • Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design
    Luca Giovanella, Federica D’Aurizio, Petra Petranović Ovčariček
    Journal of Clinical Medicine.2025; 14(16): 5645.     CrossRef
  • Determinants of circulating calcitonin value: analysis of thyroid features, demographic data, anthropometric characteristics, comorbidities, medications, and smoking habits in a population with histological full exclusion of medullary thyroid carcinoma
    Pierpaolo Trimboli, Giuseppe Peloni, Dorotea Confalonieri, Elena Gamarra, Tommaso Piticchio, Francesco Frasca, Petra Makovac, Arnoldo Piccardo, Lorenzo Ruinelli
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Surgical treatment of solid variant of papillary thyroid carcinoma: Fifteen-year experience of a tertiary center
    Katarina Tausanović, Marina Stojanović, Milan Jovanović, Boban Stepanović, Jovan Ilić, Sara Ivaniš, Vladan Živaljević
    Medicinska istrazivanja.2024; 57(1): 121.     CrossRef
  • Impact of dietary, lifestyle and sociodemographic factors on calcitonin levels in a healthy population
    Ivana Gunjača, Mirjana Babić Leko, Nikolina Pleić, Ante Jurić, Dubravka Brdar, Vesela Torlak, Marko Vuletić, Ante Punda, Ozren Polašek, Caroline Hayward, Tatijana Zemunik
    Bone.2024; 187: 117214.     CrossRef
  • Some genetic differences in patients with rheumatoid arthritis
    Hosam M. Ahmad, Zaki M. Zaki, Asmaa S. Mohamed, Amr E. Ahmed
    BMC Research Notes.2023;[Epub]     CrossRef
  • Presence or severity of Hashimoto’s thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank
    M. Cvek, A. Punda, M. Brekalo, M. Plosnić, A. Barić, D. Kaličanin, L. Brčić, M. Vuletić, I. Gunjača, V. Torlak Lovrić, V. Škrabić, V. Boraska Perica
    Journal of Endocrinological Investigation.2022; 45(3): 597.     CrossRef
  • Environmental Factors That Affect Parathyroid Hormone and Calcitonin Levels
    Mirjana Babić Leko, Nikolina Pleić, Ivana Gunjača, Tatijana Zemunik
    International Journal of Molecular Sciences.2021; 23(1): 44.     CrossRef
Close layer
Clinical Study
Impact of the Dynamic Change of Metabolic Health Status on the Incident Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Jung A Kim, Da Hye Kim, Seon Mee Kim, Yong Gyu Park, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi, Kyungdo Han, Hye Jin Yoo
Endocrinol Metab. 2019;34(4):406-414.   Published online December 23, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.4.406
  • 11,634 View
  • 100 Download
  • 23 Web of Science
  • 27 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Metabolically healthy obese (MHO) is regarded as a transient concept. We examined the effect of the dynamic change of metabolic health status on the incidence of type 2 diabetes mellitus (T2DM) both in obese and normal weight individuals.

Methods

We analyzed 3,479,514 metabolically healthy subjects aged over 20 years from the Korean National Health Screening Program, who underwent health examination between 2009 and 2010, with a follow-up after 4 years. The relative risk for T2DM incidence until the December 2017 was compared among the four groups: stable metabolically healthy normal weight (MHNW), unstable MHNW, stable MHO, and unstable MHO.

Results

During the 4 years, 11.1% of subjects in the MHNW group, and 31.5% in the MHO group converted to a metabolically unhealthy phenotype. In the multivariate adjusted model, the unstable MHO group showed the highest risk of T2DM (hazard ratio [HR], 4.67; 95% confidence interval [CI], 4.58 to 4.77). The unstable MHNW group had a higher risk of T2DM than stable MHO group ([HR, 3.23; 95% CI, 3.16 to 3.30] vs. [HR, 1.81; 95% CI, 1.76 to 1.85]). The stable MHO group showed a higher risk of T2DM than the stable MHNW group. The influence of the transition into a metabolically unhealthy phenotype on T2DM incidence was greater in subjects with aged <65 years, women, and those with weight gain.

Conclusion

Metabolically healthy phenotype was transient both in normal weight and obese individuals. Maintaining metabolic health was critical for the prevention of T2DM, irrespective of their baseline body mass index.

Citations

Citations to this article as recorded by  
  • Association between albumin-bilirubin (ALBI) score and metabolically healthy obesity among US adults: findings from NHANES 2005–2018
    Chenyi Ji, Fang Liu
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • Metabolic health phenotypes and cardiovascular disease among U.S. adults with central obesity: Evidence from NHANES 2011– March 2020
    David Kweku Aseda Donkor, Emmanuel Amoako Agyei, Samuel Prince Osei, Frederick Frimpong Opuni, Evelyn Gyau-Boakye, Maxwell Emmie, Adwoa Benyiwah Amoah, Sandra Agyenim Boateng, Dennis Dela Tsagli, Eunice Akomaning
    Obesity Pillars.2026; 18: 100267.     CrossRef
  • Dynamic Changes in Metabolic Syndrome Severity Score and Its Components with Risk of Type 2 Diabetes Mellitus: Insights from Joint Longitudinal and Survival Modeling
    Safdar Masoumi, Ebrahim Hajizadeh, Farzad Eskandari, Davood Khalili
    Metabolic Syndrome and Related Disorders.2026; 24(6): 258.     CrossRef
  • Sex-stratified associations of TyG index and HOMA-IR changes with incident type 2 diabetes
    Sojin Kim, Sujeong Shin, Yoosoo Chang, Eunju Sung, Jae-Heon Kang
    Scientific Reports.2026;[Epub]     CrossRef
  • Association of obesity phenotypes with risk of cardiovascular disease mortality: a prospective cohort study
    Ruixue Song, Yanfeng Jiang, Jiaojiao Pang, Shuo Wu, Jingjing Ma, Ping Li, Xiaohui Wu, Feng Xu, Jiali Wang, Xingdong Chen, Yuguo Chen
    BMC Public Health.2025;[Epub]     CrossRef
  • Dynamic Changes in Metabolic Status Are Associated With Risk of Ocular Motor Cranial Nerve Palsies
    Daye Diana Choi, Kyung-Ah Park, Kyungdo Han, Sei Yeul Oh
    Journal of Neuro-Ophthalmology.2024; 44(3): 386.     CrossRef
  • Metabolically healthy obese individuals are still at high risk for diabetes: Application of the marginal structural model
    Hye Ah Lee, Hyesook Park
    Diabetes, Obesity and Metabolism.2024; 26(2): 431.     CrossRef
  • The prevalence of metabolically healthy obesity and its transition into the unhealthy state: A 5‐year follow‐up study
    Amir Baniasad, Mohammad Javad Najafzadeh, Hamid Najafipour, Mohammad Hossein Gozashti
    Clinical Obesity.2024;[Epub]     CrossRef
  • When Being Lean Is Not Enough: The Metabolically Unhealthy Normal Weight Phenotype and Cardiometabolic Disease
    Dahyun Park, Min-Jeong Shin, Faidon Magkos
    CardioMetabolic Syndrome Journal.2024; 4(2): 57.     CrossRef
  • Association of anthropometric parameters as a risk factor for development of diabetic retinopathy in patients with diabetes mellitus
    Aditya Verma, Ashok Jha, Ahmed Roshdy Alagorie, Rishi Sharma
    Eye.2023; 37(2): 303.     CrossRef
  • From Metabolic Syndrome to Type 2 Diabetes in Youth
    Dario Iafusco, Roberto Franceschi, Alice Maguolo, Salvatore Guercio Nuzio, Antonino Crinò, Maurizio Delvecchio, Lorenzo Iughetti, Claudio Maffeis, Valeria Calcaterra, Melania Manco
    Children.2023; 10(3): 516.     CrossRef
  • Assessment of Metabolic Syndrome Risk Based on Body Size Phenotype in Korean Adults: Analysis of Community-based Cohort Data
    Ji Young Kim, Youngran Yang
    Research in Community and Public Health Nursing.2023; 34: 158.     CrossRef
  • Prevalence and factors related to the metabolically obese normalweight (MONW) phenotype: a review
    Edyta Suliga, Martyna Głuszek-Osuch, Stanisław Głuszek
    Medical Studies.2023; 39(1): 73.     CrossRef
  • New metabolic health definition might not be a reliable predictor for diabetes in the nonobese Chinese population
    Liying Li, Ziqiong Wang, Haiyan Ruan, Muxin Zhang, Linxia Zhou, Xin Wei, Ye Zhu, Jiafu Wei, Xiaoping Chen, Sen He
    Diabetes Research and Clinical Practice.2022; 184: 109213.     CrossRef
  • Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus?
    Qi Wu, Ming-Feng Xia, Xin Gao
    World Journal of Diabetes.2022; 13(2): 70.     CrossRef
  • Metabolically obese phenotype and its dynamic change are associated with increased carotid intima-media thickness: Results from a cohort study
    Liping Yang, Xue Li, Li Wang, Shan Xu, Yanmei Lou, Fulan Hu
    Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(9): 2238.     CrossRef
  • Obesity Metabolic Phenotype, Changes in Time and Risk of Diabetes Mellitus in an Observational Prospective Study on General Population
    Chan Yang, Xiaowei Liu, Yuanyuan Dang, Juan Li, Jingyun Jing, Di Tian, Jiangwei Qiu, Jiaxing Zhang, Ni Yan, Xiuying Liu, Yi Zhao, Yuhong Zhang
    International Journal of Public Health.2022;[Epub]     CrossRef
  • Implications of metabolic health status and obesity on the risk of kidney cancer: A nationwide population-based cohort study
    Yun Kyung Cho, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Metabolic health is a determining factor for incident colorectal cancer in the obese population: A nationwide population‐based cohort study
    Yun Kyung Cho, Jiwoo Lee, Hwi Seung Kim, Joong‐Yeol Park, Woo Je Lee, Ye‐Jee Kim, Chang Hee Jung
    Cancer Medicine.2021; 10(1): 220.     CrossRef
  • Cumulative Exposure to Metabolic Syndrome Components and the Risk of Dementia: A Nationwide Population-Based Study
    Yunjung Cho, Kyungdo Han, Da Hye Kim, Yong-Moon Park, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Endocrinology and Metabolism.2021; 36(2): 424.     CrossRef
  • Excessive Intake of High-Fructose Corn Syrup Drinks Induces Impaired Glucose Tolerance
    Hidemi Hattori, Yuma Hanai, Yuto Oshima, Hiroaki Kataoka, Nozomu Eto
    Biomedicines.2021; 9(5): 541.     CrossRef
  • The risk of Alzheimer’s disease according to dynamic changes in metabolic health and obesity: a nationwide population-based cohort study
    Yun Kyung Cho, Jiwoo Lee, Hwi Seung Kim, Joong-Yeol Park, Woo Je Lee, Ye-Jee Kim, Chang Hee Jung
    Aging.2021; 13(13): 16974.     CrossRef
  • Metabolically healthy obesity: predictors of transformation to unhealthy phenotype in St Petersburg population (according to the ESSE-RF study)
    M. A. Boyarinova, O. P. Rotar, A. M. Erina, N. A. Paskar, A. S. Alieva, E. V. Moguchaia, E. P. Kolesova, A. O. Konradi
    "Arterial’naya Gipertenziya" ("Arterial Hypertension").2021; 27(3): 279.     CrossRef
  • Physiological and Lifestyle Traits of Metabolic Dysfunction in the Absence of Obesity
    Hanna Bjørk Klitgaard, Jesper Hoffmann Kilbak, Erica Arhnung Nozawa, Ann V. Seidel, Faidon Magkos
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity
    Tenzin D. Dagpo, Christopher J. Nolan, Viviane Delghingaro-Augusto
    Cells.2020; 9(7): 1596.     CrossRef
  • Prepregnancy smoking and the risk of gestational diabetes requiring insulin therapy
    Mee Kyoung Kim, Kyungdo Han, Sang Youn You, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Obesity with and without type 2 diabetes: are there differences in obesity history, lifestyle factors or concomitant pathology?
    E. A. Shestakova, Yu. I. Yashkov, O. Yu. Rebrova, M. V. Kats, M. D. Samsonova, I. I. Dedov
    Obesity and metabolism.2020; 17(4): 332.     CrossRef
Close layer
Case Report
A Case of Multiple Osteoporotic Compression Fractures in Young Man with Budd-Chiari Syndrome.
Sun Hwa Kim, Tae Un Yang, Byeong Kwang Choi, Hye Jin Yoo, Ji A Seo, Kyung Mook Choi, Nan Hee Kim, Sin Gon Kim, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
Endocrinol Metab. 2012;27(4):334-339.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.334
  • 3,367 View
  • 31 Download
AbstractAbstract PDF
Osteoporosis in young men is extremely rare. In this report, we demonstrate a rare case of multiple vertebral fractures discovered in a young man with Budd-Chiari syndrome without prior history of trauma. A 29-year-old man was diagnosed as Budd-Chiari syndrome 12 years ago and underwent a mesocaval shunt to relieve the hepatic vein obstruction and was on warfarin therapy. He suffered from low back pain and it was not relieved by analgesics. A T-L spine X-ray revealed multiple compression fractures and the z-score at lumbar spine was -3.7 which is below the expected range for that age. The patient was treated with calcium, vitamin D and bisphosphonate, and showed clinical improvement. This case highlights the importance of the investigation for secondary osteoporosis in young adults with an underlying disease that alters bone metabolism.
Close layer
Original Article
Thyroid Dysfunction of North Korean Women Living in South Korea, Focusing on Subclinical Hypothyroidism.
Joo Hyung Kim, Sol Ah Park, Nam Hoon Kim, Jae Hee Ahn, Yoon Jung Kim, Myongjin Cho, Yoon Jung Lee, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim
Endocrinol Metab. 2012;27(3):200-207.   Published online September 19, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.3.200
  • 10,162 View
  • 32 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
Thyroid function depends on ethnic and environmental factors. North Korean refugees have the same genetic background as South Koreans, but they have been exposed to different environments. This study examines the prevalence and pattern of thyroid disorders in North Korean women living in South Korea, focusing on subclinical hypothyroidism (SCH). METHODS: The intended sample was a total of 327 North Korean women residing in Seoul. Health questionnaires and medical examinations, including serum thyrotropin (thyroid stimulating hormone, TSH), free thyroxine, and thyroid autoantibodies, were conducted. RESULTS: The prevalence of SCH was 9.4%. In logistic regression analysis, smoking, menopause, length of stay in South Korea, body mass index, history of thyroid disease, and metabolic syndrome were not associated with the risk of SCH. Whereas, the positivity of autoantibodies were associated with a high risk for SCH (odds ratio [OR], 4.840; 95% confidence interval [CI], 1.80-13.017; P = 0.002), and age was associated with a low risk for SCH (OR, 0.94; 95% CI, 0.888-0.994; P = 0.031). The serum TSH levels also decreased with increasing age, and in particular, there was significant difference between 30-39 years, and over 60 years (2.33 +/- 1.51 microIU/mL vs. 1.54 +/- 0.73 microIU/mL, P = 0.028). CONCLUSION: In North Korean women, the positivity of autoantibodies was associated with a high risk for SCH. But interestingly, a younger age was associated with a high risk for SCH. Considering that they suffered from severe famine at the period of growth, and this led to malnutrition, their thyroid dysfunction might be associated with the peculiar environment that they experienced.

Citations

Citations to this article as recorded by  
  • Systematic review of evidence on public health in the Democratic People’s Republic of Korea
    John J Park, Ah-Young Lim, Hyung-Soon Ahn, Andrew I Kim, Soyoung Choi, David HW Oh, Owen Lee-Park, Sharon Y Kim, Sun Jae Jung, Jesse B Bump, Rifat Atun, Hee Young Shin, Kee B Park
    BMJ Global Health.2019; 4(2): e001133.     CrossRef
  • Environmental Factors and Thyroid Dysfunction
    Hyun-Kyung Chung
    Endocrinology and Metabolism.2012; 27(3): 191.     CrossRef
Close layer
Editorial
Impact of the Serum Adiponectin Concentration on the Progression of Carotid Atherosclerosis in Patient with Type 2 Diabetes Mellitus.
Hye Jin Yoo, Kyung Mook Choi
Endocrinol Metab. 2012;27(1):28-30.   Published online March 1, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.1.28
  • 2,829 View
  • 20 Download
AbstractAbstract PDF
No abstract available.
Close layer
Case Reports
Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer.
Jae Hee Ahn, Sun Young Kim, Ye Ji Kim, Suk Young Lee, Jae Hyoung Lee, Seung Hun Kang, Ho Cheol Hong, Sae Jeong Yang, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Hae Yoon Choi
Endocrinol Metab. 2011;26(4):345-347.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.345
  • 6,205 View
  • 23 Download
  • 1 Crossref
AbstractAbstract PDF
Scanning with whole-body 131I scintigraphy after surgery has been a valuable diagnostic modality in the surveillance of patients with differentiated thyroid cancer. Radioiodine uptake is rarely observed in non-lactating breast tissue, which mimics thyroid cancer metastasis. We now report a case of a 45-year-old female thyroid cancer patient who underwent radioiodine therapy, and in whom breast uptake of radioiodine was observed on a post-therapy whole body scan. Her serum prolactin level was elevated to 328 ng/mL at the time of the radioiodine uptake, and the hyperprolactinemia was induced by her antipsychotic medications. Six months after she discontinued that medication, her serum prolactin level was normalized to 12.6 ng/mL and breast uptake of iodine was no longer present in a follow-up whole body scan.

Citations

Citations to this article as recorded by  
  • Incidental Findings of Intense Radioiodine Uptake in Struma Ovarii and Bilateral Nonlactating Breasts Simultaneously on Postablation 131I SPECT/CT for Papillary Thyroid Cancer
    Hye-kyung Shim, Mi Ra Kim
    Nuclear Medicine and Molecular Imaging.2016; 50(4): 353.     CrossRef
Close layer
Successful Localization of Distant Metastasis in Parathyroid Carcinoma Using Intraoperative Parathyroid Hormone Assay.
Ho Cheol Hong, Sun Won Kim, Tae Hyung Kim, In Hye Cha, Jae Hee Ahn, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Hyun Koo Kim, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Jae Bok Lee, Sei Hyun Baik, Dong Seop Choi
Endocrinol Metab. 2011;26(1):92-96.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.92
  • 3,791 View
  • 24 Download
  • 1 Crossref
AbstractAbstract PDF
Intra-operative parathyroid hormone (IOPTH) assay is a useful tool to confirm complete excision of all hyper-functioning parathyroid gland tissue. In this report, we describe a case with successful localization of distant metastasis in a patient with parathyroid carcinoma using the IOPTH assay. A 53-year-old man presented to our clinic with a serum calcium level of 11.8 mg/dL and an intact PTH level of 233.3 pg/mL. He had been treated for parathyroid carcinoma eleven years ago. Two suspected metastatic lesions were detected on the chest computed tomography. Due to the vastly different surgical field necessary to excise each lesion, we preferentially removed only one lesion and we monitored the other remaining suspected lesion without resection via IOPTH assay. Six months later, the patient's serum calcium and intact PTH levels remained within their normal ranges. To the best of our knowledge, this is the first case to effectively utilize IOPTH assay for the management of metastatic parathyroid carcinoma.

Citations

Citations to this article as recorded by  
  • The association of abdominal obesity, obesity and parathyroid hormone in Korean adults (aged≥50 years): The Korea National Health and Nutrition Survey, 2011
    Kyu Su Lee, Yo Sang Yoon, Hyun Yoon
    Journal of the Korea Academia-Industrial cooperation Society.2015; 16(6): 3882.     CrossRef
Close layer
Two Cases of Acromegaly with Empty Sella Syndrome Treated by Long-Acting Release Octreotide.
Dong Jin Kim, Young Jin Seo, Nam Hoon Kim, Hye Soo Chung, Chai Ryoung Eun, Hye Jung Choi, Hye Sook Kim, Sae Jeong Yang, Juri Park, Hye Jin Yoo, Soo Yeon Park, Yun Jeong Lee, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2007;22(2):135-141.   Published online April 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.2.135
  • 3,678 View
  • 37 Download
AbstractAbstract PDF
Two cases of typical acromegaly with empty sella syndrome presented to our institution. In the natural course of untreated pituitary adenoma, empty sella syndrome may result from necrosis by infarction or from hemorrhage of the pituitary gland. In our patients, the secretion of growth hormone continued in spite of the existence of empty sella syndrome. In one case, we confirmed the hypersecretion of growth hormone from sella by jugular vein sampling. Medical therapy with somatostatin analogue was attempted because there was no obvious mass in the sella. After 6~12 months of treatment with long-acting release octreotide, clinical features in our patients were improved, and the level of growth hormone and IGF-1 were also normalized.
Close layer
Original Article
Comparison of Target Organ Damages between Primary Aldosteronism and Essential Hypertension.
Juri Park, Dong Jin Kim, Sae Jeong Yang, Sook Hae Kim, Soo Yeon Park, Hye Jin Yoo, Yun Jeong Lee, Hee Young Kim, Ohk Hyun Ryu, Kye Won Lee, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2007;22(1):11-18.   Published online February 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.1.11
  • 3,983 View
  • 21 Download
  • 3 Crossref
AbstractAbstract PDF
BACKGROUND
A number of recent clinical studies have reported marked target organ damages in patients with primary aldosteronism. The aim of this study was to compare the incidence of target organ damages in patients with primary aldosteronism (PA) and essential hypertension (EHT). METHODS: The clinical records of 41 PA patients, over a 20-year period, were retrospectively analyzed. The clinical characteristics and incidence of target organ damages of 33 of the patients in this group were compared with those of 66 patients with essential hypertension, directly matched for age, gender and mean blood pressure. 8 of the PA patients could not be matched with EHT patients for age, gender and mean blood pressure, so were excluded from the comparison. The patients with essential hypertension were sampled from patients who visited for the evaluation of hypertension. RESULTS: Ischemic heart diseases were found in 18.2 and 10.6% of patients with PA and EHT, respectively (P = 0.22). From echocardiograms, left ventricular hypertrophy was found in 93.3% and 61.4% of patients with PA and EHT, respectively (P = 0.017). The degrees of left ventricular hypertrophy were correlated with the levels of serum aldosterone, with an r value of 0.490 (P < 0.005). Cerebrovascular attack was found in 18.2% and 1.5% of patients with PA and EHT, respectively (P = 0.005). Hypertensive retinopathy was found in 50% and 33.3% of patients with PA and EHT (P = 0.255), and nephropathy was found in 42.4% and 25.8% of patients with PA and EHT, respectively (P = 0.074). CONCLUSION: Patients with primary aldosteronism had target organ damages more frequently than with those with essential hypertension, which was independent of blood pressure.

Citations

Citations to this article as recorded by  
  • Changes in the clinical manifestations of primary aldosteronism
    Sun Hwa Kim, Jae Hee Ahn, Ho Cheol Hong, Hae Yoon Choi, Yoon Jung Kim, Nam Hoon Kim, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Nan Hee Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
    The Korean Journal of Internal Medicine.2014; 29(2): 217.     CrossRef
  • Comparing the Prevalence of Primary Aldosteronism in Hypertensive Diabetic and Non-diabetic Patients
    Yi Sun Jang, Koon Soon Kim, Hye Soo Kim
    Journal of Korean Endocrine Society.2009; 24(4): 254.     CrossRef
  • Aldosterone as a Cardiovascular Risk Factor
    Soon Jib Yoo
    Journal of Korean Endocrine Society.2007; 22(1): 8.     CrossRef
Close layer
Case Reports
A Case of Sheehan's Syndrome Presenting Central Diabetes Insipidus.
Dong Jin Kim, Nan Hee Kim, Ju Ri Park, Sae Jeong Yang, Hye Suk Kim, Hye Jin Yoo, Soo Yeon Park, Ohk Hyun Ryu, Kye Won Lee, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2006;21(4):333-337.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.333
  • 3,612 View
  • 30 Download
AbstractAbstract PDF
Sheehan's syndrome occurs as a result of ischemic pituitary necrosis due to severe postpartum hemorrhage. The manifestations of this clinical syndrome are most often caused by a deficiency in the hormones produced by the anterior pituitary gland, whereas the neurohypophysis is usually preserved but can be involved in severe cases that manifest as diabetes insipidus. This is a report of Sheehan's syndrome that manifested with diabetes insipidus as presenting symptom 2 month's after delivery. The patient suffered massive bleeding, so received a blood transfusion. A combined pituitary stimulation and water deprivation test revealed deficiencies of not only anterior pituitary hormones, such as growth hormone and prolactin, but also of anti-diuretic hormone. We report this case, with a review of the literature.
Close layer
A Case of Primary Hyperparathyroidism Caused by Cystic Parathyroid Adenoma, Diagnosed during Intra-Operative PTH Monitoring.
Hye Jin Yoo, Nan Hee Kim, Soo Yeon Park, Dong Jin Kim, Sae Jeung Yang, Ju Ri Park, Hee Young Kim, Ji A Seo, Kye Won Lee, Sin Gon Kim, Kyung Mook Choi, Jae Bok Lee, Young Seok Lee, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2005;20(3):278-282.   Published online June 1, 2005
DOI: https://doi.org/10.3803/jkes.2005.20.3.278
  • 2,872 View
  • 27 Download
AbstractAbstract PDF
Primary hyperparathyroidism is the most frequent cause of hypercalcemia, and its prevalence is increasing due to the routine examination of serum calcium levels. Primary hyperparathyroidims is most commonly caused by an adenoma or hyperplasia of the parathyroid gland. A cystic parathyroid adenoma is an extremely rare cause of primary hyperparathyroidism. In our case, a-79-year old female presented with lower back pain and constipation. Her serum calcium, phosphate and immunoreactive parathyroid homone levels were 15.6, 1.8mg/dL and 371.8pg/mL, respectively. Neck CT revealed a cystic mass and a contour bulging heterogeneous mass in the left inferior right thyroid gland, respectively. These mass lesions were removed, and the intra-operative parathyroid hormone levels monitored, to confirm the complete resection. After removing the left cystic mass to the inferior thyroid, the serum calcium and immunoreactive parathyroid hormone levels quickly returned to normal. We report a case of primary hyperparathyroidism, caused by a cystic parathyroid adenoma, with a brief review of the literature
Close layer
A Case of Congenital Adrenal Hyperplasia due to 11beta-Hydroxylase Deficiency.
Ohk Hyun Ryu, Hye Jin Yoo, Soo Yeon Park, Soon Beom Kwon, Sang Soo Park, Hee Young Kim, Kye Won Lee, Ji A Seo, Jeong Heon Oh, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi
J Korean Endocr Soc. 2004;19(1):58-63.   Published online February 1, 2004
  • 2,339 View
  • 49 Download
AbstractAbstract PDF
Congenital adrenal hyperplasia refers to a group of autosomal recessive disorders that is defective in the synthesis of cortisol. The enzymes most often affected are 21-hydroxylase and 11beta hydroxylase. The low levels of cortisol stimulate the pituitary gland to release ACTH. Chronic elevation of the ACTH level causes bilateral adrenal hyperplasia and a secondary increase in androgen formation. We examined a 19 year-old woman presented with clitoral hypertrophy and vaginal spotting. The subjects basal level of serum cortisol was low, but the serum levels of ACTH, 17a-hydroxyprogesterone, deoxy-corticosterone were elevated. The urinary excretions of 17-ketosteroids and 17-hydroxycorticosteroids were also increased. The karyotyping study and transrectal ultrasonography showed normal findings. The patient underwent clitoris reduction surgery and received hydrocortisone. To the best of our knowledge, this is the first case of 11beta-Hydroxylase deficiency in Korea.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP